BioWorld: The Daily Biopharmaceutical and Medical Technology …
These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn.
BioWorld: The Daily Biopharmaceutical News Source
6 days ago · With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors.
BioWorld Science: The Daily Drug R&D News Source
Daily news focused on drug discovery, delivery and preclinical research. Coverage includes: Congress highlights, key studies from peer-reviewed journals, chemical structure images, pharmacology news that delineates drug/receptor and enzyme/target cell interactions, newly reported experimental models, and relationships between genes and diseases to gain insight into underlying biological ...
Regulatory actions for December 24, 2024 | BioWorld
4 days ago · Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Accord, Celltrion, CSL Berhing, Everest, Eli Lilly, Innovent, Mesoblast, Merck.
Today's news in brief | BioWorld
5 days ago · BioWorld briefs for Dec. 24, 2024.
Welcome to the new BioWorld Science
Sep 12, 2022 · BioWorld Science has now been migrated onto the same platform as the full suite of BioWorld news services, providing an improved experience and expanded news offering. The new site features many enhancements, which you can read about here.Frequently Asked Questions are answered here. In addition to BioWorld Science content, you can now read headlines and summaries from the flagship news ...
Other news to note for Jan. 29, 2024 | BioWorld
Jan 29, 2024 · Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ABL, Cristalia, Debiopharm, Formosa, Gamida Cell, Institut ...
China - Articles - BioWorld
5 days ago · China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs.
Cancer - Articles - BioWorld
Dec 20, 2024 · The BioWorld Biopharmaceutical Index (BBI) closed November with a modest 3.58% gain for the year, a sharp decline from its 16.92% rise in September and peak of 25.19% in August. The BBI has now fallen behind the Nasdaq Biotechnology Index, which posted a 6.27% year-to-date gain, and the Dow Jones Industrial Average, up 19.16% at the end of the month.
| BioWorld
Oct 17, 2024 · As a new BioWorld new investigative report shows, decades of research excluding women from clinical trials and investment decisions made in male-dominated boardrooms have led to half the world’s health needs being underserved.Of the drug development companies working on women's health solutions, the proportion of …